Leerink Swann, Cowen and Co. assist in financing corporate purposes
By Devika Patel
Knoxville, Tenn., March 2 - Amicus Therapeutics, Inc. priced a $57 million public offering of stock with an $8.55 million greenshoe in a prospectus supplement filed Friday with the Securities and Exchange Commission. The deal was announced Thursday.
The company will sell 10 million common shares at $5.70 per share. The price per share is a 4.36% discount to $5.96, the March 1 closing share price.
Leerink Swann LLC and Cowen and Co., LLC are the underwriters.
Settlement is expected on March 7.
Proceeds will be used for general corporate purposes.
Amicus is a Cranbury, N.J., biopharmaceutical company.
| Issuer: | Amicus Therapeutics, Inc
|
| Issue: | Common stock
|
| Amount: | $57 million
|
| Greenshoe: | $8.55 million
|
| Shares: | 10 million
|
| Price: | $5.70
|
| Warrants: | No
|
| Underwriters: | Leerink Swann LLC and Cowen and Co., LLC
|
| Announcement date: | March 1
|
| Pricing date: | March 2
|
| Settlement date: | March 7
|
| Stock symbol: | Nasdaq: FOLD
|
| Stock price: | $5.96 at close March 1
|
| Market capitalization: | $204.63 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
